Hence, disruption of PD-1/PD-L1/PD-L2 signaling with PD-1 blocking monoclonal antibodies has become an attractive strategy to harness the immune effector cells anti-tumor potential in lymphoma as well as solid organ malignancy [28,29,30]. Here, CD274 is linked to lymphoma.